Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday

Key Points

• Biomea Fusion is expected to report Q1 2026 results on May 4, 2026 before the market opens, with analysts forecasting an EPS loss of ($0.23)
• The stock opened at $1.89 with a market capitalization of $136.65 million, a 12‑month range of $0.87–$3.08, and 50/200‑day moving averages of $1.50 and $1.38, respectively.
• Institutional investors own about 96.72% of the float, and analyst consensus is a "Moderate Buy" with an average price target of $9.57.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) is expected to issue its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 4, 2026 at 4:00 PM ET.

Biomea Fusion Price Performance

BMEA opened at $1.89 on Monday. The firm has a market capitalization of $136.65 million, a P/E ratio of -1.44 and a beta of -0.25. The stock's 50 day moving average price is $1.50 and its two-hundred day moving average price is $1.38. Biomea Fusion has a 12-month low of $0.87 and a 12-month high of $3.08.

Institutional Trading of Biomea Fusion

Institutional investors have recently modified their holdings of the company. Scientech Research LLC acquired a new stake in shares of Biomea Fusion during the 3rd quarter worth approximately $25,000. Engineers Gate Manager LP acquired a new stake in shares of Biomea Fusion during the 2nd quarter valued at about $26,000. Millennium Management LLC boosted its position in shares of Biomea Fusion by 156.7% during the 4th quarter. Millennium Management LLC now owns 25,677 shares of the company's stock valued at $32,000 after acquiring an additional 15,675 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Biomea Fusion during the 3rd quarter valued at about $39,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Biomea Fusion during the 4th quarter valued at about $54,000. Institutional investors and hedge funds own 96.72% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Biomea Fusion in a research report on Tuesday, January 13th. They issued a "buy" rating and a $8.00 price target on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Biomea Fusion in a report on Monday, April 20th. D. Boral Capital restated a "buy" rating and set a $12.00 price objective on shares of Biomea Fusion in a report on Wednesday, April 8th. Wall Street Zen upgraded shares of Biomea Fusion from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. Finally, Citigroup boosted their price objective on shares of Biomea Fusion from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $9.57.

Biomea Fusion Company Profile

Biomea Fusion, Inc NASDAQ: BMEA is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company's lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.